throbber
Petitioner Amerigen Pharmaceuticals Ltd.
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 1
`
`

`
`Petitioner Amerigen Pharmaceuticals Ltd.
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 2
`
`

`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 3
`Petitioner Amerigen Pharmaceuticals Ltd.
`
`

`
`Petitioner Amerigen Pharmaceuticals Ltd.
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 4
`
`

`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 5
`Petitioner Amerigen Pharmaceuticals Ltd.
`
`

`
`W0 92/08459
`
`PCT/SE91 /00760
`
`Examples of suitable "alkenyl"groups include vinyl (ethenyl), 1-
`gpropenyl,
`i-butenyl, pentenyl, hexenyl, n-decenyl and c-pentenyl and
`the like.
`
`The groups may be substituted, generally with 1 or 2 substituents,
`wherein the substituents are independently selected from halo,
`hydroxy, alkoxy, amino, mono- and dialkylamino, nitro, carboxyl,
`alkoxycarbonyl, and cyano groups.
`
`By the expression "phenalkyl groups wherein the alkyl moiety
`contains 1-3 carbon atoms "
`is meant benzyl, phenethyl and 1
`phenylpropyl groups wherein the phenyl moiety may be substituted.
`When substituted,
`the phenyl moiety of the phenalkyl group may
`, contain, independently from 1
`to 3 alkyl, hydroxy, alkoxy, halo, amino,
`mono- and dialkylamino, nitro, carboxyl, alkoxycarbonyl and cyano
`groups.
`
`Examples of suitable "heteroaryl" are pyridinyl,
`
`thienyl or imidazolyl.
`
`As noted herein, the expression "halo" is meant
`sense to include F, Cl, Br, and l.
`
`in the conventional
`
`The term "non-toxic pharmaceutically acceptable acid addition salts"
`as used herein generally includes the non-toxic addition salts of
`7
`compounds of Formula I, formed with non-toxic inorganic or organic
`acids. For example, the salts include those derived from inorganic
`acids such as hydrochloric, hydrobromic, sulphuric, sulphamic, nitric,
`phosphoric and the like; and the salts with organic acids such as
`acetic, propionic, succinic,
`fumaric, maleic,
`tartaric, citric, glycolic,
`lactic, stearic, malic, pamoic, ascorbic, phenylacetic, benzoic,
`glutamic, salicylic, sulphanilic, methanesulphonic, and the like.
`
`The inventive method for relieving pain and for tranquilizing
`mammals comprises the application of the above compositions to
`mammalian skin and in particular, provides for inducing and
`maintaining analgesia by administering through an area of intact skin
`a morphine prodrug of the Formula I at an analgetically effective rate
`and continuing the administration of said material at said rate for an
`extended period of time at least sufficient to induce analgesia. Said
`compositions may contain any type of absorption enhancers, such as
`ifatty acids, fatty acid esters and fatty alcohols as well as any type
`of pharmaceutical additive commonly used for topical or dermal
`preparations and/or delivery systems such, as transdermal patches.
`
`lt
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 6
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 6
`
`

`
`W0 92/08459
`
`5
`
`PC!‘/SE91/00760
`
`is an object of the present invention to provide an improved method
`of treating and controlling acute and/or chronic pain.
`It
`is a further object of the present invention to enable pain to be
`controlled over a sustained period of time by administering
`transdermally a morphine prodrug of Formula I.
`According to the present
`invention,
`the permeability coefficients and
`fluxes of the compounds and compositions through mammalian skin
`tissue are established as being sufficient
`in magnitude to be
`practical
`for direct
`transdermal applications, producing time-
`sustained dosage rates consistent for pain suppression and
`tranquilizing effects over prolonged periods of
`time.
`The morphine prodrug derivatives of the present
`invention are certain
`derivatives which show a higher lipophilicity and biphase solubility
`than the active parent drug and hence are better able to penetrate the
`skin of a human or non-human animal and which are capable of
`reverting to the active morphine during or after transportation
`through the skin. These characteristics make the derivatives useful
`for transdermal delivery of morphine.
`
`Figures 1 and 2 show the permeability of some morphine esters
`through human skin. The amount of morphine appearing in the receptor
`phase is plotted as a function of time from suspensions or solutions
`of 3,6-dipropionyl morphine (A),
`(figure 1) and dihexanoyl morphine
`(B), (figure 2) in 0.05 M phosphate buffer of pH 7.0 (O) and isopropyl
`myristate(-).
`3,6-Dipropionyl morphine was applied in the form of suspensions in
`both buffer and IPM whereas 3,6-dihexanoyl morphine was applied in
`buffer and as a solution (200mg/ml) in IPM.
`
`DETAILED DESCRIPTION OF THE INVENTION
`
`Among the compounds represented by the general Formula I, preferred
`compounds are such in which R1 and R2 are the same and is one of the
`following groups:
`acetyl
`.
`propionyl
`butyryl
`valeryl
`hexanoyl
`isobutyryl
`methoxyacetyl
`ethoxyacetyl
`benzoyl
`nicotinoyl
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 7
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 7
`
`

`
`W0 92/08459
`
`1
`
`z
`
`6
`
`PCT/SE9l/00760
`
`methoxycarbonyl
`ethoxycarbonyl
`propoxycarbonyl
`butoxycarbonyl
`hexyloxycarbonyl
`octyloxycarbonyl
`imidazolylcarbonyl
`
`Other preferred compounds are such in which R1 is hydrogen and R2 is
`one of the groups listed above, or R2 is hydrogen and R1 is one of
`these, groups.
`9
`7
`
`7
`
`The compounds of Formula I are esters (carboxylic acid or carbonate
`esters) of morphine formed either at C3 or C5, or at both hydroxyl
`groups. Several esters of morphine have long been known including
`the -3,6-diacetyl ester (heroin) and 3,6-dinicotinoyl ester
`(nicomorphine).
`Information on the preparation or pharmacological
`8
`activity of various esters of morphine can thus be found in the
`5
`following references: Beckett and Wright (1875), Hesse (1884), Merck
`(1899), Emde (1930), Mannich and Siewert (1939), Welsh (1954), Zirm
`and Pongratz (1959), Pongratzand Zirm (1957, 1964), Voldeng et al.
`(1968), Selmeci et al. (1968), Borowitz and Diakiw (1975), May and
`Jacobsen (1977), Andrew et al. (1984), Owen et al. (1984), Sy et al.
`(1986), Broekkamp et al. (1988) and Whitehouse et al. (1990). See
`reference list on page 12.
`However,
`these references or other information in the literature do
`not disclose orindicate any utility of esters or other derivatives of
`morphine as prodrug forms suitablefor transdermal delivery of
`morphine, nor any properties of the compounds that might indicate
`such utility.
`Asuwill be described below it has now surprisingly been found that
`compounds of Formula I
`-
`in contrast to morphine itself — are highly
`useful
`to achieve transdermal delivery of morphine at an
`analgetically effective rate and extent.
`
`7
`
`6
`
`Emparatign gf Qgmpgunds of Formula I
`
`4 The compounds of Formula I can be prepared by various methods as
`already described in the literature for a number of morphine esters
`(see the references cited above). Thus, we prepared 3,6-dipropionyl,
`3,6-diisobutyryl and 3,6-dihexanoyl morphine by reacting morphine
`with an excess of the corresponding acid anhydride, following the
`method described by Owen et al.
`
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 8
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 8
`
`

`
`W0 92/08459
`
`PCT/S E9 1 /00760
`
`and the
`6-Propionyl morphine was prepared as described by Sy et al.
`3-propionyl, 3-isobutyryl and 3-hexanoyl esters as described by
`Welsh.
`
`Detailed descriptions of the preparation of some morphine esters are
`given in Examples 1-5.
`
`F¢a.m.o_|e_1
`
`3,6-dipropionyi morphine (Formula l, R1 = R2 = C2H5CO)
`
`A mixture of morphine (2.0 g) and propionic anhydride (5.0 ml) was
`stirred at 90 °C for 4 h.-Upon cooling to room temperature water (40
`ml) was added. After 1 h the solution was partitioned between ether
`(50 ml) and 10 % potassium hydroxide solution (40 ml). The ether
`phase was separated, washed with water, dried over anhydrous
`sodium sulphate and evaporated in vacuo. The residue obtained was
`crystallized form ethanol-water to yield 2.7 g of the title compound,
`m.p. 106-107 °C.
`
`Example 2
`
`3-propionyl morphine (Formula I, R1 = C2H5CO,R2 =H)
`
`Propionic anhydride (13.1 ml, 100 mmol) was added while stirring to
`a mixture of sodium bicarbonate (20 g, 240 mmol) and morphine
`hydrochloride(3.75g, 10mmol)
`in water (200 ml). After complete
`addition the mixture was stirred for 90 min and extracted with
`
`chloroform (2 x 100 ml). The combined extracts were dried over
`anhydrous sodium sulphate and evaporated in vacuo to yield the title
`compound as a colorless oil
`in 95% yield. The compound crystallized
`from petroleum ether at -18°C, m.p. 85-86°C( Anal.
`: calc./w
`C2oH23NO4: C,70.36; H,6.79; N,4.10. Found: C,70.35; H,6.89, N,4.19.).
`The hydrochloric acid salt of the compound was prepared by adding a
`methanolic HCl solution to a solution of the base in ether, m.p. 157-
`158 °C (monohydrate).
`
`Exam.o.le_.3
`
`3,6-diisobutyryl morphine (Formula I, R1 = R2 = (CH3)2CH2CO)
`
`The compound was prepared essentially as described in Example 1,
`using isobutyric anhydride instead of propionic anhydride. The
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 9
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 9
`
`

`
`W0 92/08459
`
`PCT/SE91 /00760
`
`compound was recrystallized from ether-petroleumeether, m.p. 96-97
`°C.
`0
`6
`
`x m l 4
`
`3,6—dlhexanoylTmorphine (Formula I, R1 = R2 = CH3(CH2)4CO)
`
`The compound was prepared essentially as described in Example 1,
`using hexanoic anhydride instead of propionic anhydride. The
`compound was a colorless oil.
`
`g
`
`3-hexanoyl morphine (Formula I, R1 = CH3(CH2)4CO, R2= H)
`
`The compound was prepared essentially as described in Example 2,
`using the equivalent amount of hexanoic anhydride instead of
`propionic anhydride. The compound was a colorless oil.
`
`0
`r.
`fMrhin
`hilii
`Li
`n
`ili
`l
`in water at
`The solubility of the compounds, given in Examples 1-5,
`pH 7 and in isopropyl myristate and their partition coefficients
`between octanol and pH 7.4 aqueous buffer (P) are shown in Table 1.
`The experimental methods used for these determinations are
`described below.
`1
`6
`
`Table 1 §olubilities and gagtition goefficignjgs
`
`(P) of morphine and
`
`v
`
`I
`
`r
`
`r
`
`r
`
`1 6°
`
`4
`
`Compound
`
`0
`
`log P 51
`
`Morphine.
`.3-Propionyl-morphine
`3,6-Dipropionyl-morphine
`3-Hexanoyl-morphine
`P 3,6-Diisobutyryl-morphine
`3,6-Dihexanoyl-morphine
`
`-0.06
`0.66
`1.66
`2.04
`2.60
`>4
`
`§olubility
`In Water
`
`4
`
`(mg/ml)
`ln IPM b
`
`.
`
`at
`
`pH 7.0
`
`1.8 P
`21
`3.6
`2.6
`0.6
`0.02
`
`0.023
`7 9
`4 1
`>150
`8 0
`
`>200
`
`a Between octanol and pH 7.4 aqueous buffer.
`b IMP:
`isopropyl myristate
`1
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 10
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 10
`
`

`
`W0 92/08459
`
`PC!‘/S E91 /00760
`
`The solubilities of morphine and morphine esters were determined in
`triplicate in a phosphate buffer solution of pH 7.0 and in isopropyi
`myristate (IPM) at 21 °C by placing excess amounts of the compounds
`in 5 ml of the solvent. The mixtures were placed in an ultrasonic bath
`for 10 min and then rotated on a mechanical spindle for 24 h and
`filtered. After rotation for 1
`h the pH of the phosphate buffer
`mixtures was adjusted to 7.0. An aliquot of the filtrates was diluted
`with water or acetonitrile and analyzed by HPLC.
`
`The apparent partition coefficients (P) of morphine and the various
`esters were determined at 21°C in an octanol-0.02 M phosphate
`buffer (pH 7.4) system. The concentration of the compounds in the
`aqueous phase before and after partitioning was determined by HPLC
`analysis, and the partition coefficients determined.
`
`it can readily be seen that the
`From the data shown in Table 1
`morphine esters are more lipophilic than the parent drug in terms of
`octanol-aqueous buffer partition coefficients.
`It
`is also apparent
`that
`morphine esters showing both increased water and lipid solubility
`relative to morphine can be obtained. This higher biphasic solubility
`may be most favourable for skin penetration.
`
`kin
`
`rm
`
`i n
`
`i
`
`The feasibility of achieving transdermal delivery of morphine via the
`prodrugs of the present invention was evaluated by diffusion
`experiments in vitro using human skin samples.
`Whole abdominal human skin obtained under autopsy from two donors
`was used. The skin was stored at -18 °C and was allowed to thaw
`gradually at room temperature before use. All subcutaneous fat was
`removed and the skin cut into pieces. The excised skin was mounted
`in open Franz diffusion cells. They have an available diffusion area of
`0.70 cm?.
`The dermal side of the skin was exposed to the receptor medium (7.5
`ml of 0.05 M isotonic phosphate buffer of pH 7.2) which was stirred
`magnetically and kept at a constant temperature of 37 °C with a
`circulating water bath.
`The compounds studied were applied as solutions or suspensions (200
`microliter)
`in an aqueous buffer (pH 7.0) or in isopropyi myristate
`(lPM).
`The suspensions were stirred for 24 h prior to application to the skin
`surface. Samples of 2 ml were removed from the receptor phase and
`replaced with fresh buffer at appropriate intervals. The samples
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 11
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 11
`
`

`
`W0 92/08459
`
`1 0
`
`PCT/SE91/00760
`
`were storedat -20 °C until analyzed for their morphine, di- and/or
`monoester content by HPLC as described below. The permeation
`studies of each compound were done in tri- or quadruplicate.
`P
`Reversed-phase HPLC procedures were used for the quantitative
`determination of morphine and its esters. A deactivated Supelcosil
`column was eluted with a mobile phase consisting of a mixture of
`acetonitrile (15-70 % v/v) and 0.01 M phosphate buffer solution of pH
`6.5. The concentration of acetonitrile was adjusted for each
`compoundito give a suitable compound retention time (3-10 min). The
`flow rate was 1.0 ml/min and the column effluent was monitored at
`215 or 280 nm.
`It was assured that in each case adequate separation
`of the ester from morphine and monoesters (in the case of the
`diesters) was achieved. Quantitation of the compounds was done from
`measurements of the peak heights in relation to those of standards
`chromatographed under the same conditions.
`in the case of morphine no measurable amounts of drug could be
`detected in the receptor phase during diffusion experiments lasting
`up to 200 h. The failure of morphine to penetrate human skin from the
`vehicles applied in significant amounts is in accordance with the
`g
`results obtained by Roy and Flynn (1989). These authors reported a
`steady—state flux of 0.006 ug /cm2/h for the permeation of morphine
`through human skin from a saturated solution of the drug in a pH 7.4
`buffer.
`the 3-hexanoyl, 3,6-dihexanoyl and other 3,6-dipropionyl
`in contrast,
`morphine esters readily penetrated human skin. The results obtained
`with some of these derivatives are shown in Fig.
`1
`in which the
`cumulative amounts (in mg morphine base) of morphine or ester
`measured in the receptor phase divided by the surface area of the
`diffusion cell are plotted against the time of ‘sampling. The steady-
`state fluxes were obtained from the slopes of the linear portions of
`these plots. The permeability coefficients (Km for the steady—state
`delivery were obtained by dividing the steady—state fluxes by the
`solubilities or concentrations of the compounds in the vehicle
`applied. The values obtained for various morphine esters, using
`morphine as a reference, are given in Table 2.
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 12
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 12
`
`

`
`W0 92/08459
`
`PCT/SE91 /00760
`
`1 1
`
`r
`f
`K
`i n
`ffi
`ili
`rm
`n
`Fl
`I
`phase gf delivery gf morphine thrgugh human skin frgm isoprogyl
`i
`I M
`n
`n
`ff
`r
`f H 7.
`
`-
`
`Compound
`
`Flux(ug/cm?/h)
`
`Kp(cm/h)
`
`IMP
`
`Buffer
`
`lPM
`
`Buffer
`
`Morphine
`3.6-Dipropionyl-morphinea
`3,6-Dihexanoyl-morphine
`3-Hexanoyl-morphine
`3-Proprionyl-morphine
`3-Acetyl-morphine
`3-lsobutyryl-morphine
`3-Valeryl-morphine
`3-Butoxy-morphine
`
`<o.o1
`<o.o1
`2.5 -1; 0.5
`8.7 i 0.4
`1.7 : 0.2
`11.7 : 1.2b
`35.6 i12.0° 25.3 i 4.2
`37.7 i 4.1
`11.4 i 1.8b
`27.0 i 3.3b
`16.5 : 2.7b
`8.3 :t 2.2b
`
`<4.3 x 10'4
`3.0 x 1O'4
`>1.6 x 10-4
`>2.4 x 10-4
`
`<5.5 x 10‘5
`1.0 x 10-3
`0.14
`1.3 x 10'?
`
`Approximately 50 % of the amounts penetrated were present in the
`a
`receptor phase as morphine and 50 % as the 6-monoester. The flux values
`given were calculated in terms of total morphine equivalents.
`b
`The IPM solution applied was not saturated.
`It contained the
`compound at a concentration of 200 mg/ml
`c
`The IPM solution applied was not saturated.
`compound at a concentration of 125 mg/ml
`For all cases except the 3,6-diproprionyl ester, only morphine was
`found in the receptor phase, whereas for the 3,6-dipropionyl ester
`approximately 50 % of the amounts penetrated were present in the
`receptor phase as morphine and 50 % as the corresponding 6-
`monoester.
`it
`is of great interest to note the appreciable skin
`enzyme-mediated hydrolysis of the esters during diffusion.
`
`It contained the
`
`An experiment with 3-Proprionyl-morphine dissolved in ethanol-
`water (3:1 vol/vol) at a concentration of 620 mg/ml revealed a flux
`of 1021-8.0ug/cm2/h.
`
`The results obtained from the human skin permeation experiments
`show that it
`is possible to a very high degree improve the skin
`a
`penetration of morphine via prodrugs. Thus,
`the 3-hexanoyl ester
`afforded a more than 2.000-fold higher flux relative to morphine
`itself when delivered from an aqueous buffer vehicle, and
`progressevly greater enhancement was achieved when isopropyl
`myristate was used as a vehicle. The increased solubility of the
`esters in the vehicles (Table 1) combined with expected concomitant
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 13
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 13
`
`

`
`WO 92/08459
`
`1 2
`
`PCT/SE91/00760
`
`for transdermal delivery is 25 cm? and if a flux of 25
`example,
`microgram/h/cm? is used(see Table 2),
`it would be possible to
`deliver 0.625 mg morphine/h or 15 mg over 24 h. This amount is
`higher than that usually administrated (10 mg) parenterally during 24
`hours.
`
`The actual administration or use of the transdermal analgesic
`compositions according to the present invention can be in any
`conventional form and may follow any of the methods generally
`known to the art. For instance,
`the active narcotic analgetic
`compound (i.e., a morphine prodrug of Formula l) can be used in
`association with any pharmaceutical dosage form such as,
`for
`example, but not
`limited thereto, any solution, ointment,
`lotion,
`paste,
`jelly, gel, cream, spray or aerosol generally known tothe art.
`As such,
`the narcotic analgetic prodrug form in association with the
`pharmaceutical dosage formican be used directly as a topical
`composition or used in combination with an additional drug delivery
`device, for example, but not
`limited thereto, patches, gauze,
`compresses, or the like, again, as generally known in the art. The
`dosage forms may contain any type of absorption enhancers such as
`fatty acids, fatty acid esters and fatty alcohols or any other non-
`toxic compounds which are known to increase skin .permeability.
`in
`particular,
`the transdermal analgesic compositions can be
`administered in the form of a patch wherein the active morphine
`Vprodrug agent is present in a polymeric matrix or in a reservoir
`system combined with a polymeric rate controlling membrane.
`
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 3 Page 14
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 14
`
`

`
`8 W0 92/08459
`
`PCT/SE9l/00760
`
`13
`
`B_e.fs=.m_0.e:-L._l1s.I
`
`Andrew, R., Tasker, R. and Nakatsu, K.
`Evaluation of 3,6-dibutanoylmorphine as an analgesic in vivo:
`comparison with morphine and 3.6-diacetyl morphine.
`Life Sci. 34 (1984) 1659-1667
`
`Beckett, G.H. and Wright, C.R.A.,
`Action of the organic acids and their anhydrides on the natural
`alkaloids. Part
`ll.
`
`J. Chem. Soc. 28 (1875) 15-26
`
`|.J. and Diakiw, V.,
`Borowitz,
`The preparation and synthetic utility of 0-substituted
`normethylmorphines.
`J. Heterocycl. Chem., 12 (1975) 1123-1126.
`
`Broekkamp, C.L., Oosterloo, S.K. and Rijk, H.W.,
`Prodrug behaviour of nicotinoylmorphine esters.
`J. Pharm. Pharmacol. 40 (1988) 434-437.
`
`_E_mde,H.,
`Uber Diastereomerie VI. Konfiguration der Morphinalkaloide.
`Helv. Chim. Acta, 13 (1930) 1035-1058.
`
`Hesse, 0.,
`Studien iJber Morphin.
`Ann. Chem., 222 (1884),203-234.
`
`Mannich, C. and Siewert, G., Uber 6-Benzoyl-morphln.
`Arch. Pharm., 277 (1939) 128-130.
`
`May, E.L. and Jackson, A.E.,
`Chemistry and pharmacology of homologs of 6-acetyl and 3,6-
`diacetylmorphine.
`J. Pharm. Sci., 66 (1977) 285-286.
`
`Merck, E.,
`Ueber einige Morphinderivate.
`Arch. Pharm., 237 (1899) 211-222.
`
`Owen, J.A., Elliott, J., Jhamandas, K., and Nakatsu, K.,
`Morphine diesters,
`l. Synthesis and action on guinea pig ileum.
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 15
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 15
`
`

`
`two 92/08459
`
`1 4
`
`PCT/SE91/00760
`
`Can. J. Physiol. Pharmacol., 62 (1984) 446-451.
`
`Pongratz, A. and Zirm, K.L.,
`Verfahren zur Darstellung des neuen 6-Morphin
`Mononicotinsaureesters.
`Osterr. Patentschrift Nr. 234,914 (1964).
`
`Pongratz, A. and Zirm, K.L.,
`Monatsh., 88 (1957) 330.
`
`VI
`
`Selmeci, G., Szlavik, L., Kaskoto, Z., Lepenyene, J.M. and Tothne, A.l.,
`Synthesis of new derivatives of morphine.
`ll. Production of
`benzoylmorphines with analgesic action and benzylmorphine
`possessing morphine-potentiating activity.
`Khim. Farm. Zh., 2 (7) (1968) 19-23
`
`Sy, W.-W., By, A.W., Neville, G.A. and Wilson, W.L.,
`Syntheses of 3-O- and 6-O-propanoylmorphine - a reinvestigation and
`correction.
`
`J. Pharm. Sci., 75 (1986) 787-789.
`
`Voldeng, A.N., Brandley, A., Kee, R.D., King, E.L. and (Melder, F.L.,
`Synthesis of adamantyl analoga of analgesics.
`J. Pharm. Sci., 57 (1968) 1053-1055.
`
`Welsh, L.H.,
`O3-Monoacetylmorphine.
`J. Org. Chem., 19 (1954) 1409-1415.
`
`Whitehouse, L.W., Paul, C.J., Gottschling, K.H., Lodge, B.A. and By, A.W.,
`Antinociceptive activity of propionyl esters of morphine: a
`reevaluation.
`1
`
`J. Pharm. Sci., 79 (1990) 349-350.
`
`Zirm, K.L.c and Pongratz, A.,
`Zur Wirkung des Pyridin-3-Carbonséiurebiesters des Morphines als
`Analgeticum.
`T
`Arzneim.-Forsch., 9 (1959) 511-513.
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 16
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 16
`
`

`
`W0 92/08459
`
`PCT/S E91 /00760
`
`15
`
`g\
`
`CLAIMS
`
`A topical composition for transdermal delivery of morphine
`1.
`comprising an effective amount of a compound of the formula:
`
`
`
`wherein R1 and R2 are the same or different and are hydrogen and a
`member selected from the group of physiologically hydrolyzable
`chemical groups consisting of alkylcarbonyl,alkenylcarbonyl
`arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl and
`heteroaryloxycarbonyl groups wherein the alkyl moiety consists of
`unsubstituted and substituted, straight-chain and branched-chain and
`cyclic alkyl groups having 1-20 carbon atoms, wherein the alkenyl
`moiety consists of unsubstituted and substituted, straight-chain and
`branched-chain and cyclic alkenyl groups having 2-20 carbon atoms,
`wherein the aryl moiety consists of
`unsubstituted and substituted
`phenyl, and phenalkyl groups wherein the alkyl moiety contains 1-3
`carbon atoms and the phenyl moiety is unsubstituted or substituted,
`and the heteroaryl moiety is an aromatic 5- or 6-membered
`heterocyclic ring containing one or two heteroatoms selected from
`the group consisting of nitrogen, oxygen, and sulfur;
`and nontoxic pharmaceutically acceptable acid addition salts thereof,
`with the proviso that if R1 = hydrogen then R2 ¢ hydrogen, and if R2 =
`hydrogen then R1 at hydrogen
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 17
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 17
`
`

`
`W0 92/08459
`
`16
`
`g
`
`PCT/SE91/00760
`
`in association with a topical pharmaceutical carrier which gives
`solutions, suspensions, ointments,
`lotions, creams, gels, pastes,
`jellies, sprays and aerosols and/or together with a medical device.
`
`A composition according to Claim 1 wherein R1 and R2 each are
`2.
`acetyl, propionyl, butyryl,
`isobutyryl, valeryl, hexanoyl, octanoyl,
`as
`ethoxyacetyl, methoxycarbonyl, ethoxycarbonyl, or benzoyl.
`
`A composition according to Claim 2 wherein R1 is hydrogen and
`3.
`R2 is as claimed in Claim 2.
`A
`
`A composition according to Claim 2 wherein R2
`4.
`R1 is as claimed in Claim 2.
`A
`
`is hydrogen and
`
`5. A composition according to any of claims 1-4
`toxic additive acting as a skin penetration enhancer.
`
`containing a non-
`
`A topical dosage form consisting of a matrix type or reservoir
`6.
`type patch system containing a compound according to Formula I
`as
`defined in claim 1.
`A
`
`A topical dosage form consisting of a compound according to
`7.
`Formula I
`as defined
`in claim 1
`in combination with a penetration .
`enhancing delivery device/process such as iontophoresis.
`
`A topical dosage form in which the composition according to
`8.
`any of claims 1-4 is combined with an additional drug delivery device
`such as patches, gauze or compresses.
`
`in as defined in claim 1
`Use of the esters according to Formula I
`9.
`for the manufacture. of a topical medicament for transdermal delivery
`for relieving pain or tranquilizing a mammal.
`A
`
`10. Use of the esters according to Formula I as defined in claim 1
`for
`transdermal delivery.
`
`A process for achieving transdermal delivery of morphine
`11.
`comprising the application to mammalian skin of an effective amount
`of a composition according to any of claims 1-4.
`
`VJ
`
`4)
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 18
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 18
`
`

`
`W0 92/08459
`
`PCT/S E91 /00760
`
`1/2
`
`Figure 1
`
`3 L
`
`D
`1-!
`
`$ $‘
`
`-1
`
`3 O
`
`J 5
`
`-p-I
`
`I-
`
`$ L
`
`O
`
`3
`3
`3
`‘-1
`

`L1‘)
`|\
`
`$
`CD
`LE7
`
`$
`LI")
`("U
`
`$
`
`3
`
`(aw:/fin) paqeuqauad qunowv
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 19
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 19
`
`

`
`W0 92/08459
`
`PCT/S E9 1 /00760
`
`2 / 2
`
`Figure 2
`
`$ L
`
`O
`‘-1
`
`$ ©1
`
`-!
`
`CD
`LO
`
`$
`
`3 D
`
`J E
`
`-v—l
`
`}:
`
`2000
`
`1500
`
`1000
`
`50
`
`(aw:/fin) paqeJ1auad qunowv
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 20
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 20
`
`

`
`|NTERNAT1ONAL.SEARCH REPORT
`
`International Application No
`I. CLASSIFICATION OF SUBJECT MATTER (it several classitlcation symbols apply, indicate all)
`
`According to International Patent classification (IPC) or to both National classification and IPC
`IPC5: A 61 K 31/485, 47/00, 9/70
`
`II. FIELDS SEARCHED
`
`Minimum Documentation Searched7
`classification symbols
`
`
`
`
` IPC5
`
`Documentation searched other than Minimum Documentation
`to the Extent that such Documents are Included in Fields Searched“
`
`
` R
`
`SE,DK,FI,N0 classes as above
`III. "DOCUMENTS CONSIDERED TO BE RELEVANT9
`
`elevant to Claim No.13
`
`Citation of Document," with indication, where appropriate, of the relevant passages 12
`
`EP, A2, 0171742 (E.I. DU PONT DE NEMOURS AND
`COMPANY) 19 February 1986,
`see the whole document
`
`
`
`
`
`
`
`
`
`W0, A1, 9115241 (MORIMOTD, Y) 17 October 1991,
`see the whole document
`
`
` Pharmaceutical Research, Vol. 6, No. 10, 1989 Samir
`
`D. Roy et al.: "Transdermal Delivery of
`
`Narcotic Analgesics: comparative Permeabilities
`of Narcotic Analgesics Through Human Cadaver
`Skin",
`see page 825 - page 832
`
`
`
`A 61 K
`
`
`
`
`
`
`
`
`
`
`
`
`
`Chemical Abstracts, volume 112, no. 10, 5 March
`1990,
`(Columbus, Ohio, US), Rieg-Falson, F. et
`al.: "Characterization of the enhancing effect
`of a rehicle in a transdermal system ", see
`page 433, abstract 84017c, & Drug. Dev. Ind.
`Pharm. 1989, 15(14), 2393-2406
`
`
`
`-
`I
`“ special categories of cited docilnents: 1°
`'A' ggggmggd‘fg'g'e“g"g:
`I:'‘‘lf3''gf:5°m?ge''‘° "" which ‘3 "'3'
`' '
`I
`it
`Hit
`blished
`raltertheinternafonal
`E
`5*-7-'3»-:°5i-«%°"'"°“
`" '"‘
`°" °
`'
`'1: document which may throw doubts pn iiori
`cIaim(s or
`which is cited to es alilish the public: iop_da e of aiio her
`.
`-
`-
`-
`citation or other special reason (as specified)
`"O' document relernng to an oral disclosure, use, exhibition or
`other means
`
`no I
`B I
`I
`I H
`'1'’ gItDll’_lg%p’|;I2:{|eI ililiiglis ed‘ aclgfiifigiamfiimationalggtigg git;
`ganlundentand the principle or theory uiegerlying the
`.
`.
`.
`.
`"‘ 22:::,".°.:':::..e:i.:L$:t:..:sL*:v::::;.:.'a':.sL=;':::2.:2ai'::"
`i“V°'V9 3" i"V°"“V9 "PP
`,Y, document at "maul" lance‘ the claimed invemion
`n
`n or more o
`u-
`gmnm mi Fonfldgreddm ‘we've an mvanuyf flap “men the
`m°§,',’¢';"°;'m':f, €f',',{',b{n:m‘,",','
`,,e?,,§ obvious to ,°,',';,'s'g,, safued
`in me "1.
`
`';i)is’i“:iei"i,t;'di:{etgl:i|ifnEatdtem'fi°n'I min“ “'8 hm '&' document member at the same patent tamily
`f:t‘i:a‘il'"t1l?a"i:
`‘P.
`IV. CERTIFICATION
`
`Date ol the Actual completion of the International Search
`
`Date at Mailing ol this lntemational Search Report
`
`7th February 1992
`lntemational Searching Authority
`
`
`
`
`
`
`
`
`
`
`
`
`
`iggg -82- 1 2
`Signature 0!
`orized Officer
`7% ea/Meek,
` S.EDISH PA
`a Johansson
`
`NT 0
`PFICE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 21
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 21
`
`

`
`FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET
`
`International Application No.
`
`7
`
`V. I2 OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE1
`This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:
`LE Claim number:’......1.l., because they relate to subject matter not required to be searched by this Authority, namely:
`See PCT Rule 39.1(iv): Methods for treatment of’
`the
`human or animal body by surgery or therapy, as well as
`diagnostic methods.
`
`
`
`
`
` 2 7
`-
`
`Claim numbers..........., because they relate to parts of the international application, that do not comply with the prescribed
`requirements to such an extent that no meaningful international search can be carried out, specifically:
`,
`
` 3 D Claim numbers........... because they are dependent claims and are not drafted in accordance with the second and third sen-
`

`
`tences of PCT Rule s.4(a).
`
`I
`
`
`
`This lntemational Searching Authority found multiple inventions in this international application as follows:
`
`VI. D OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING 2
`
`
`
` 1 D As ,all required additional search fees were timely paid by the applicant, this international search report covers all searchable
`
`-
`
`claims of the international application.
`
`,
`
`
`
`
`,
`the
`_
`this international search report covers
`applicant
`
` 2_ As only some _of the requjred additional search fees were timely paid by_
`only those claims of the international application for wtiic
`fees were paid, specifically claims:
`
`
`
`
`
` 3. El 2.?’ i%°?i’§'?.?v2fi?§$i.°i‘.‘r;??n‘£fiiiJ§§§ }'3°':"nE=."i‘n°e"'ci3-.‘i‘.§‘.s'3"ii"3§ S5’5’.'=‘ri'ii“i;y‘f=?£‘.’rfi”.i'.i.?:'i':‘éis'§“‘ “""'"’“°“" “""°" ""’°" I‘ '°""°“
`
`
`
`4 D As all s.ear_cI'iable claims could be searched without effort justifying an additional fee, the International Searching Authority
`-
`did not invite payment of any additonal fee.
`Remark on Protest
`
`
`[I The additional search fees were accompanied by applicant's protest.
`D No protest accompanied the payment of additional seach tees.
` Form PCT/ISA/Z10 tsuppleuental sheet (2)) (January 1985)
`
`
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 22
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 22
`
`

`
`ANNEX TO THEINTERNATWONAL SEARCH REPORT
`
`ON INTERNATIONAL PATENT APPLICATION NO.PCT/SE 91/00760
`
`This annex lists the patent family members relating to the patent documents cited in the above-menticyed international search report.
`The members are as contained in the Swedish Patent Office EDP file on
`9
`The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.
`
`Patent document
`cited in search report
`
`Publication
`date
`
`Patent family
`memherts)
`
`Publication
`date
`
`EP-A2- 0171742
`
`86-02-19
`
`'
`
`AU-B-
`AU-D-
`JP-A-
`US-A-
`
`574628
`4590585
`61083116
`4626539
`
`88-07-07
`86-02-13
`86-04-26
`86-12-02
`
`W0-A1- 9115241
`
`91-10-17
`
`*5v
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1020 - Page 23
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1020 — Page 23

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket